ATE132195T1 - Rekombinant-mykobakterielle impfstoffe - Google Patents

Rekombinant-mykobakterielle impfstoffe

Info

Publication number
ATE132195T1
ATE132195T1 AT88903026T AT88903026T ATE132195T1 AT E132195 T1 ATE132195 T1 AT E132195T1 AT 88903026 T AT88903026 T AT 88903026T AT 88903026 T AT88903026 T AT 88903026T AT E132195 T1 ATE132195 T1 AT E132195T1
Authority
AT
Austria
Prior art keywords
replicates
useful
recombinant mycobacterial
shuttle vector
vaccine vehicles
Prior art date
Application number
AT88903026T
Other languages
English (en)
Inventor
Barry R Bloom
Ronald W Davis
William R Jacobs Jr
Richard A Young
Original Assignee
Whitehead Biomedical Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Biomedical Inst filed Critical Whitehead Biomedical Inst
Application granted granted Critical
Publication of ATE132195T1 publication Critical patent/ATE132195T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/32—Mycobacterium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT88903026T 1987-03-02 1988-02-29 Rekombinant-mykobakterielle impfstoffe ATE132195T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2045187A 1987-03-02 1987-03-02

Publications (1)

Publication Number Publication Date
ATE132195T1 true ATE132195T1 (de) 1996-01-15

Family

ID=21798698

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88903026T ATE132195T1 (de) 1987-03-02 1988-02-29 Rekombinant-mykobakterielle impfstoffe

Country Status (6)

Country Link
EP (2) EP0681026A1 (de)
JP (2) JP3011939B2 (de)
AT (1) ATE132195T1 (de)
CA (1) CA1336270C (de)
DE (1) DE3854840D1 (de)
WO (1) WO1988006626A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015873A1 (en) * 1989-06-19 1990-12-27 Whitehead Institute For Biomedical Research Vector-mediated genomic insertion and expression of dna in bcg
US5504005A (en) * 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
US5807723A (en) * 1987-03-02 1998-09-15 Whitehead Institute For Biomedical Research Homologously recombinant slow growing mycobacteria and uses therefor
EP0486495A1 (de) * 1989-03-08 1992-05-27 Commonwealth Scientific And Industrial Research Organisation Expressionssystem für aktinomyceten und verwandte organismen
DE69027956T2 (de) * 1989-05-31 1997-03-06 Ajinomoto Kk Sekretorische Expressionsvektoren für Mycobakterien sowie Transformanten
JP2903414B2 (ja) * 1989-05-31 1999-06-07 味の素株式会社 抗酸菌分泌発現ベクター及び抗酸菌
WO1991013157A1 (en) * 1990-02-26 1991-09-05 Commonwealth Scientific And Industrial Research Organisation Shuttle plasmid for escherichia coli and mycobacteria
CA2045842A1 (en) * 1990-07-16 1992-01-17 William R. Jacobs Dna capable of site-specific integration into mycobacteria
EP0587765A4 (de) * 1991-06-06 1994-11-02 Medimmune Inc Induktion der immunantwort gegen das tetanustoxin durch verarbeitung von mycobakterien, die das tetanustoxin oder fragmente davon exprimieren.
WO1992021376A1 (en) * 1991-06-06 1992-12-10 Med Immune, Inc. Induction of ctl responses to foreign antigens expressed in mycobacteria
US6566121B1 (en) 1991-06-13 2003-05-20 Albert Einstein College Of Medicine Of Yeshiva University Insertional mutations in mycobacteria
EP0590027A4 (de) * 1991-06-13 1994-10-19 Einstein Coll Med Mutationen in mycobakterien durch geneinbau.
JPH07502646A (ja) * 1991-10-21 1995-03-23 メディミューン，インコーポレーテッド リポタンパク質の分泌シグナルをコード化するｄｎａを含む細菌発現ベクター
EP0728764A4 (de) * 1993-10-19 1999-01-20 Ajinomoto Kk Peptide das eine immunantwort gegen hiv unduziert und arzneimittel die esenthaelt zur vorbeugung oder behandlung von aids
US7300660B2 (en) 1993-11-23 2007-11-27 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
JPH09505588A (ja) 1993-11-23 1997-06-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 多くの細胞外生成物及びそれらの製造法並びに使用
US6752993B1 (en) 1993-11-23 2004-06-22 The Regents Of The University Of California Abundant extracellular product vaccines and methods for their production and use
US6013660A (en) * 1996-10-02 2000-01-11 The Regents Of The University Of California Externally targeted prophylactic and chemotherapeutic method and agents
US6221364B1 (en) * 1996-11-12 2001-04-24 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacteria auxotrophic for diaminopimelate
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US5972700A (en) * 1997-09-26 1999-10-26 Albert Einstein College Of Medicine Of Yeshiva University TM4 conditional shuttle phasmids and uses thereof
KR100503438B1 (ko) * 1998-06-12 2005-09-26 에스케이케미칼주식회사 테레프탈산의 제조방법
WO2000011181A1 (en) 1998-08-20 2000-03-02 Connaught Laboratories Limited NUCLEIC ACID MOLECULES ENCODING INCLUSION MEMBRANE PROTEIN C OF $i(CHLAMYDIA)
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6291190B1 (en) 1998-08-25 2001-09-18 The Board Of Trustees Of The Leland Stanford Junior University Molecular differences between species of the M. tuberculosis complex
CA2388337C (en) 1999-10-22 2013-01-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
US6924118B2 (en) * 2000-04-17 2005-08-02 The Regents Of The University Of California Recombinant intracellular pathogen immunogenic compositions and methods for use
US6471967B1 (en) * 2000-04-17 2002-10-29 The Regents Of The University Of California Recombinant intracellular pathogen vaccines and methods for use
EP1792995A3 (de) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia Antigene, entsprechende DNS Fragmente und ihre Verwendungen
DK1282702T3 (da) 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
ES2284681T3 (es) 2000-08-25 2007-11-16 Aventis Pasteur Limited Epitopos de oligosacaridos del nucleo de lipopolisacaridos de maemophilus influenzae como vacunas para la prevencion de infecciones por haemophilus influenzae.
CN1484700A (zh) 2000-11-02 2004-03-24 �¼��¹�����ѧ aopB基因,蛋白,同系物,片段和它们的变体,以及它们在细胞表面展示方面的应用
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
ES2290449T3 (es) 2002-04-09 2008-02-16 Sanofi Pasteur Limited Acido nucleico de cea modificado y vectores de expresion.
JP2005529622A (ja) 2002-06-19 2005-10-06 ヴェーイーベー・ヴェーゼットウェー 腸吸収を促進するための方法および手段
US8383132B2 (en) 2003-10-16 2013-02-26 The Regents Of The University Of California Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
DK2206514T3 (da) 2003-10-16 2014-04-22 Univ California Rekombinante intracellulære patogene immunogene sammensætninger og metoder til anvendelse
ES2405552T3 (es) 2005-11-29 2013-05-31 Actogenix N.V. Inducción de tolerancia mucosa a antiantígenos de células beta de islotes pancreáticos
WO2008090223A2 (en) 2007-01-25 2008-07-31 Actogenix N.V. Treatment of immune disease by mucosal delivery of antigens using genetically modified lactobacillus
MX2011006922A (es) 2008-12-24 2012-06-12 Netherlands Vaccine Inst Polipeptidos de neumolisina (ply) modificada a partir de streptococcus pneumonia.
US20140093556A1 (en) 2011-01-28 2014-04-03 Sanofi Pasteur Sa Immunological Compositions Against HIV
BR112014002817A2 (pt) 2011-08-08 2021-09-08 Curelab Oncology Inc Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62
DK178233B1 (en) 2012-09-17 2015-09-14 Novartis Tiergesundheit Ag Fiskevaccine
WO2014070975A1 (en) 2012-11-02 2014-05-08 Novartis Ag Flavivirus associated with theiler's disease
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
AU2014369861B2 (en) 2013-12-29 2018-09-13 Curelab Oncology, Inc. Methods and compositions relating to p62/SQSTM1 for the treatment and prevention of inflammation-associated diseases
KR102357893B1 (ko) 2014-08-05 2022-02-04 맵퀘스트 에스아 Pd-1 에 결합하는 면역학적 시약
CA3045756A1 (en) 2015-12-05 2017-06-08 Centre Hospitalier Universitaire Vaudois Hiv binding agents
ES3034233T3 (en) 2016-01-22 2025-08-14 MabQuest SA Non-blocking pd1 specific antibodies
US20220267416A1 (en) 2019-07-15 2022-08-25 Lausanne University Hospital Hiv binding agents
TWI884296B (zh) 2020-08-11 2025-05-21 美商碩騰服務公司 抗冠狀病毒疫苗
CN114315985A (zh) 2020-09-29 2022-04-12 硕腾服务有限责任公司 减毒猪流行性腹泻病毒
US20240390476A1 (en) 2021-08-31 2024-11-28 Zoetis Services Llc Attenuated alphavirus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1000787A (en) 1910-10-06 1911-08-15 Otto H Davidter Wagon-rack standard.
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
JPH0734745B2 (ja) * 1984-10-05 1995-04-19 味の素株式会社 形質導入方法
CA1238591A (en) * 1984-09-27 1988-06-28 Ramachandra N. Rao Recombinant dna cosmid shuttle vectors

Also Published As

Publication number Publication date
EP0347425A1 (de) 1989-12-27
EP0681026A1 (de) 1995-11-08
JP3011939B2 (ja) 2000-02-21
WO1988006626A1 (en) 1988-09-07
JPH02504461A (ja) 1990-12-20
EP0347425B1 (de) 1995-12-27
CA1336270C (en) 1995-07-11
DE3854840D1 (de) 1996-02-08
JPH11335296A (ja) 1999-12-07

Similar Documents

Publication Publication Date Title
ATE132195T1 (de) Rekombinant-mykobakterielle impfstoffe
DE68929507D1 (de) Rekombinante mykobakterielle expressions-träger sowie deren verwendung
JP4144813B2 (ja) Ｃｒｍ蛋白質およびジフテリアトキシンを産生させるための新規なプラスミド
US5591632A (en) Recombinant BCG
KR890701125A (ko) 무병원성 미생물 및 이의 용도
Anderson et al. Cloning and expression in Escherichia coli of the gene encoding the structural subunit of Bacteroides nodosus fimbriae
EP0625043A4 (en) Recombinant multivalent m protein vaccine.
NZ235260A (en) Borrelia burgdorferi antigens, monoclonal antibodies to these, pathogenic strain, dna encoding antigens, vectors and vaccines against lyme disease
AU2278497A (en) Novel non-pyrogenic bacterial strains and use of the same
DE69418699D1 (de) Induktion der antworten zytotoxischer t-lymphozyten
ATE120487T1 (de) Therapeutische zusammensetzungen gegen streptokokken-infektionen, transformierte wirte, verfahren zur immunisierung und gentechnologisch hergestellte produkte.
ATE250133T1 (de) Verktorvermittelte genominsertion und expression von dna in bcg
Jechlinger et al. Comparative immunogenicity of the hepatitis B virus core 149 antigen displayed on the inner and outer membrane of bacterial ghosts
IL100010A0 (en) Avirulent strain of salmonella typhi,its preparation and vaccines containing it
DE69228944D1 (de) Bovines herpesvirus typ 1rekombinantenpolypeptide und vakzine
EP0294469A4 (de) Impfstoffe und diagnosetest für haemophilus influenzae.
MY105080A (en) Heat-labile toxin b subunit fusion proteins.
AU2403188A (en) Infectious bovine rhinotracheitis virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
FR2636842B1 (fr) Proteine de fusion d'une sequence derivee de la sous-unite b de la toxine cholerique et d'un antigene heterologue doue de proprietes immunogenes, compositions de vaccins les contenant et acides nucleiques recombinants contenant une sequence de nucleotides codant pour ladite proteine de fusion
EP0432220A4 (en) Vaccines and diagnostic assays for haemophilus influenzae
AU4334193A (en) Infectious bovine rhinotracheitis virus mutants and vaccines
Lopez-Macias et al. Induction of antibodies against Salmonella typhi OmpC porin by naked DNA immunization
GR3030447T3 (en) PCTD plasmid isolated from chlamydia trachomatis serotype D, its genes and proteins encoded by them; recombinant plasmids for the expression of said genes in heterologous systems as fused recombinant proteins, preparation of said recombinant proteins and their use in the formulation of vaccines and/or dianostics
Bloom et al. Development of recombinant BCG vaccines.
ES2074965A1 (es) Virus mutante recombinante de rinotraqueitis infecciosa bovina y vacunas que lo contienen.